EU to review Merck’s targeted lung cancer drug
Tepotinib could be the first treatment on the market for NSCLC in adults harbouring METex14 skipping alterations
Read More
Tag: METex14 skipping alterations
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
